Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Successful COMPASS, Disappointing COMMANDER HF, What Have We Learned From These Two Trials?

He, Yuhu MD, PhD; Hu, Xinqun MD, PhD; Zhou, Shenghua MD, PhD

Journal of Cardiovascular Pharmacology: October 2019 - Volume 74 - Issue 4 - p 306–307
doi: 10.1097/FJC.0000000000000712
Perspectives
Buy

Abstract: Despite considerable progress in the field of heart failure about drugs and device therapy, the mortality rate of patients with heart failure remains high. Studies have shown that thromboembolism and stroke are associated with high mortality in patients with heart failure. Although warfarin therapy reduces the rate of ischemic stroke in patients with heart failure, the overall benefit from warfarin in this population seems to be offset by the increased bleeding risk. Thus, whether patients with chronic heart failure might benefit from anticoagulation, especially in patients with sinus rhythm, is still controversial. Rivaroxaban, a new oral anticoagulant, is a selective direct factor Xa inhibitor that is used to reduce thrombin generation, which may bring hope to anticoagulation in patients with heart failure. However, the COMPASS trial and recently published COMMANDER HF trial presented different results. By carefully analyzing 2 clinical trials, we think several factors might explain this different outcome.

Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Reprints: Shenghua Zhou, MD, PhD, Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China (e-mail: zhoushenghua@csu.edu.cn).

Supported by the National Natural Science Foundation of China (NSFC) (81800059).

The authors report no conflicts of interest.

Received April 20, 2019

Accepted June 20, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.